In sharp contrast, the nanomolar BCL2-specific inhibitor venetoclax (ABT-199, GDC-0199) proved effective in most hematologic malignancies and was soon approved for the therapy of patients with CLL and AML (Table 3) [65,71,72,73,74,75]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.